Aatmaj Health (AATMAJ)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 27.03% and profit growth of 64.52% show strong momentum.
• Latest quarter sales of ₹11 Cr with net profit of ₹1 Cr indicates improving profitability.
• Promoter holding of 64.33% keeps management aligned with minority shareholders.
• Piotroski F-Score of 7/9 points to generally sound financial health.
• PEG ratio of 1.23 suggests growth may partly justify the valuation.

Concerns

• P/E of 56.50 is very high, leaving little room for error.
• ROCE of only 3.39% is weak for a hospital business.
• No dividend and missing ROE, book value, and debt-equity data hinder fundamental analysis.
• Micro-cap size of ₹47 Cr makes it inherently risky and volatile.

AI Analysis

Let me look at Aatmaj Health the way I would any business. It is a hospital, a sector I understand, but the figures on the table are a mixed bag. At ₹19.70, the market values this at only ₹47 crore. That is a tiny enterprise, and in hospital business small size is often a disadvantage. There is no dividend, no book value figure, and return on capital employed is just 3.39%. That is far below what I would demand from a business with pricing power and a durable moat. The latest quarter shows sales of ₹11 crore and net profit of ₹1 crore, which is decent, but a single quarter does not make an investment. It is growing: sales up 27% and profit up 64.5%. That sounds wonderful, but at a P/E of 56.5, the market is already paying for years of excellent performance. At that price, even good growth can leave you with poor returns. The PEG ratio of 1.23 is a bit kinder, but with so many financials missing—ROE, book value, debt-equity—I cannot judge the quality of the balance sheet. The Piotroski score of 7 out of 9 does suggest the operating health has improved, and promoter holding at 64.33% is a positive sign; they are aligned. But with a 52-week range of ₹16.70 to ₹25.50, the stock trades near the middle, and I see no margin of safety. I would not call this a Buffett-style purchase. It is a small, fast-growing hospital with good momentum but heavy valuation and incomplete disclosure. I would put it on the watch list, not in the wallet.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer